JJ
Pipeline Tracker
Johnson & Johnson Pipeline Assets
Sort by:
| Asset | Therapeutic Area | MOA | Phase | Last Update | Actions |
|---|---|---|---|---|---|
|
JNJ-78436735
Ad26.COV2.S
|
Infectious Disease
COVID-19
|
Adenovirus vector vaccine
|
Approved | 2h ago | View Details |
|
TREMFYA
guselkumab
|
Immunology
Psoriasis/PsA
|
IL-23 inhibitor
|
Phase 3 | 5h ago | View Details |
|
DARZALEX
daratumumab
|
Oncology
Multiple Myeloma
|
Anti-CD38 mAb
|
Phase 3 | 8h ago | View Details |
|
SPRAVATO
esketamine
|
Neurology
Treatment-resistant depression
|
NMDA receptor antagonist
|
Approved | 1d ago | View Details |
|
JNJ-63723283
cetrelimab
|
Oncology
Solid Tumors
|
PD-1 inhibitor
|
Phase 2 | 2d ago | View Details |
Showing 1 to 5 of 24 assets
© 2025 CI Agent. All rights reserved.